Lambert Eaton Myasthenic Syndrome Market to Reach US$ 1.38 Billion by 2031, Says CoherentMI [Yahoo! Finance]
Catalyst Pharmaceuticals, Inc. (CPRX)
Last catalyst pharmaceuticals, inc. earnings: 3/16 05:26 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.catalystpharma.com
Company Research
Source: Yahoo! Finance
Burlingame, Oct. 11, 2024 (GLOBE NEWSWIRE) -- CoherentMI published a report, titled, Lambert Eaton Myasthenic Syndrome Market is estimated to value at US$ 0.09 Billion in the year 2024 , and is anticipated to reach US$ 1.38 Billion by 2031 , with growing at a CAGR of 6.35% during the forecast period 2024-2031. The Lambert Eaton Myasthenic Syndrome market has been experiencing growth due to rising diagnosis and treatment rates around the world. Lambert Eaton Myasthenic Syndrome is an autoimmune disorder affecting the connection between nerves and muscles. However, it remains quite rare and often underdiagnosed. In recent years, advances in clinical research and diagnostic techniques have helped improve detection of Lambert Eaton Myasthenic Syndrome symptoms. Another major factor spurring market growth is the emergence of novel therapeutic options for Lambert Eaton Myasthenic Syndrome. For many years, treatment was restricted to immune-suppressing medications that carried several side
Show less
Read more
Impact Snapshot
Event Time:
CPRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CPRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CPRX alerts
High impacting Catalyst Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
CPRX
News
- Catalyst Pharmaceuticals to Participate in Upcoming Investor ConferencesGlobeNewswire
- Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) is now covered by analysts at Stephens. They set an "overweight" rating and a $35.00 price target on the stock.MarketBeat
- Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Growth Stock [Yahoo! Finance]Yahoo! Finance
- Are You a Value Investor? This 1 Stock Could Be the Perfect Pick [Yahoo! Finance]Yahoo! Finance
- Catalyst Pharmaceuticals Recognized Among BioSpace 2025 Best Places to WorkGlobeNewswire
CPRX
Earnings
- 11/6/24 - Beat
CPRX
Sec Filings
- 11/22/24 - Form 4
- 11/21/24 - Form 4
- 11/20/24 - Form 144
- CPRX's page on the SEC website